Point72 Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Point72 Asset Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,500	Closed	-$1.49M	–	3899
2025 Q3	$1.49M	Buy	+7,500	New	+$1.4M	﹤0.01%	1568
2024 Q4	–	Sell	-10,000	Closed	-$1.49M	–	2072
2024 Q3	$1.49M	Buy	+10,000	New	+$1.35M	﹤0.01%	1288

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management's ASND Position: Q2 2025 in Review

Point72 Asset Management sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 569,146 shares — an estimated $88.7M sold.

Point72 Asset Management first reported a position in ASND in Q1 2020 and held it in 12 quarters. The position peaked at $88.7M in Q1 2025. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

Point72 Asset Management reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
Point72 Asset Management sold 569,146 Ascendis Pharma A/S shares in Q2 2025, an estimated $88.7M.
Point72 Asset Management first reported a position in Ascendis Pharma A/S in Q1 2020 and held it in 12 quarters.
Point72 Asset Management's Ascendis Pharma A/S position peaked at $88.7M in Q1 2025.
247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.